Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants.

ABSTRACT:

SUBMITTER: Natalucci G 

PROVIDER: S-EPMC7724553 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature